Renin-angiotensin system and cardiovascular risk

被引:523
作者
Schmieder, Roland E. [1 ]
Hilgers, Karl F. [1 ]
Schlaich, Markus P. [1 ]
Schmidt, Bemhard M. W. [1 ]
机构
[1] Univ Erlangen Nurnberg, Dept Hypertens & Nephrol, D-91054 Erlangen, Germany
关键词
END-POINT REDUCTION; CONVERTING-ENZYME-INHIBITION; FACTOR-KAPPA-B; LEFT-VENTRICULAR HYPERTROPHY; CORONARY-ARTERY-DISEASE; ENDOTHELIAL PROGENITOR CELLS; TYPE-2; DIABETIC-NEPHROPATHY; AT(1) RECEPTOR BLOCKADE; LOW-DENSITY-LIPOPROTEIN; C-REACTIVE PROTEIN;
D O I
10.1016/S0140-6736(07)60242-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The renin-angiotensin system is a major regulatory system of cardiovascular and renal function. Basic research has revealed exciting new aspects, which could lead to novel or modified therapeutic approaches. Renin-angiotensin system blockade exerts potent antiatherosclerotic effects, which are mediated by their antihypertensive, anti-inflammatory, antiproliferative, and oxidative stress lowering properties. Inhibitors of the system-ie, angiotensin converting enzyme inhibitors and angiotensin receptor blockers, are now first-line treatments for hypertensive target organ damage and progressive renal disease. Their effects are greater than expected by their ability to lower blood pressure alone. Angiotensin receptor blockers reduce the frequency of atrial fibrillation and stroke. Renin-angiotensin system blockade delays or avoids the onset of type 2 diabetes and prevents cardiovascular and renal events in diabetic patients. Thus, blockade of this system will remain a cornerstone of our strategies to reduce cardiovascular risk.
引用
收藏
页码:1208 / 1219
页数:12
相关论文
共 151 条
  • [1] The angiotensin II AT2 receptor is an AT1 receptor antagonist
    AbdAlla, S
    Lother, H
    Abdel-tawab, AM
    Quitterer, U
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (43) : 39721 - 39726
  • [2] Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes - A meta-analysis of randomized clinical trials
    Abuissa, H
    Jones, PG
    Marso, SP
    O'Keefe, JH
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (05) : 821 - 826
  • [3] METABOLISM AND PRODUCTION OF ANGIOTENSIN-I IN DIFFERENT VASCULAR BEDS IN SUBJECTS WITH HYPERTENSION
    ADMIRAAL, PJJ
    DERKX, FHM
    DANSER, AHJ
    PIETERMAN, H
    SCHALEKAMP, MADH
    [J]. HYPERTENSION, 1990, 15 (01) : 44 - 55
  • [4] Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction
    Al Suwaidi, J
    Hamasaki, S
    Higano, ST
    Nishimura, RA
    Holmes, DR
    Lerman, A
    [J]. CIRCULATION, 2000, 101 (09) : 948 - 954
  • [5] ASSOCIATION OF THE RENIN SODIUM PROFILE WITH THE RISK OF MYOCARDIAL-INFARCTION IN PATIENTS WITH HYPERTENSION
    ALDERMAN, MH
    MADHAVAN, S
    OOI, WL
    COHEN, H
    SEALEY, JE
    LARAGH, JH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (16) : 1098 - 1104
  • [6] [Anonymous], 2000, Lancet, V355, P253, DOI DOI 10.1016/S0140-6736(99)12323-7
  • [7] Angiotensin-converting enzyme inhibition restores flow-dependent and cold pressor test-induced dilations in coronary arteries of hypertensive patients
    Antony, I
    Lerebours, G
    Nitenberg, A
    [J]. CIRCULATION, 1996, 94 (12) : 3115 - 3122
  • [8] Renin inhibition with aliskiren: where are we now, and where are we going?
    Azizi, M
    Webb, R
    Nussberger, J
    Hollenberg, NK
    [J]. JOURNAL OF HYPERTENSION, 2006, 24 (02) : 243 - 256
  • [9] Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline
    Azizi, M
    Rousseau, A
    Ezan, E
    Guyene, TT
    Michelet, S
    Grognet, JM
    Lenfant, M
    Corvol, P
    Menard, J
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (03) : 839 - 844
  • [10] Stimulation of endothelial progenitor cells - A new putative therapeutic effect of angiotensin II receptor antagonists
    Bahlmann, FH
    de Groot, K
    Mueller, O
    Hertel, B
    Haller, H
    Fliser, D
    [J]. HYPERTENSION, 2005, 45 (04) : 526 - 529